Trial Profile

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitomycin (Primary)
Indications Carcinoma; Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms OLYMPUS
Sponsors UroGen Pharma

Most Recent Events

12 Feb 2025 Results presented in an UroGen Pharma Media Release.
05 Dec 2024 Results presented in an UroGen media release
26 Nov 2024 According to UroGen media release, data from the study were presented in the Journal of Urology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com